266 related articles for article (PubMed ID: 22373240)
1. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer.
Magbanua MJ; Sosa EV; Scott JH; Simko J; Collins C; Pinkel D; Ryan CJ; Park JW
BMC Cancer; 2012 Feb; 12():78. PubMed ID: 22373240
[TBL] [Abstract][Full Text] [Related]
2. Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients.
Magbanua MJ; Sosa EV; Roy R; Eisenbud LE; Scott JH; Olshen A; Pinkel D; Rugo HS; Park JW
Cancer Res; 2013 Jan; 73(1):30-40. PubMed ID: 23135909
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.
Shaffer DR; Leversha MA; Danila DC; Lin O; Gonzalez-Espinoza R; Gu B; Anand A; Smith K; Maslak P; Doyle GV; Terstappen LW; Lilja H; Heller G; Fleisher M; Scher HI
Clin Cancer Res; 2007 Apr; 13(7):2023-9. PubMed ID: 17404082
[TBL] [Abstract][Full Text] [Related]
4. Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.
Gupta S; Li J; Kemeny G; Bitting RL; Beaver J; Somarelli JA; Ware KE; Gregory S; Armstrong AJ
Clin Cancer Res; 2017 Mar; 23(5):1346-1357. PubMed ID: 27601596
[No Abstract] [Full Text] [Related]
5. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.
Reyes EE; VanderWeele DJ; Isikbay M; Duggan R; Campanile A; Stadler WM; Vander Griend DJ; Szmulewitz RZ
J Transl Med; 2014 Nov; 12():313. PubMed ID: 25424879
[TBL] [Abstract][Full Text] [Related]
6. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
[No Abstract] [Full Text] [Related]
7. Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.
Greene SB; Dago AE; Leitz LJ; Wang Y; Lee J; Werner SL; Gendreau S; Patel P; Jia S; Zhang L; Tucker EK; Malchiodi M; Graf RP; Dittamore R; Marrinucci D; Landers M
PLoS One; 2016; 11(11):e0165089. PubMed ID: 27851748
[TBL] [Abstract][Full Text] [Related]
8. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
[TBL] [Abstract][Full Text] [Related]
9. Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling.
Magbanua MJ; Park JW
Methods; 2013 Dec; 64(2):114-8. PubMed ID: 23896286
[TBL] [Abstract][Full Text] [Related]
10. A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.
García JL; Lozano R; Misiewicz-Krzeminska I; Fernández-Mateos J; Krzeminski P; Alfonso S; Marcos RA; García R; Gómez-Veiga F; Virseda Á; Herrero M; Olmos D; Cruz-Hernández JJ
Clin Transl Oncol; 2017 Nov; 19(11):1350-1357. PubMed ID: 28600675
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis.
Magbanua MJ; Melisko M; Roy R; Sosa EV; Hauranieh L; Kablanian A; Eisenbud LE; Ryazantsev A; Au A; Scott JH; Park JW
Cancer Res; 2013 Dec; 73(23):7134-43. PubMed ID: 24142343
[TBL] [Abstract][Full Text] [Related]
12. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer.
Neves RP; Raba K; Schmidt O; Honisch E; Meier-Stiegen F; Behrens B; Möhlendick B; Fehm T; Neubauer H; Klein CA; Polzer B; Sproll C; Fischer JC; Niederacher D; Stoecklein NH
Clin Chem; 2014 Oct; 60(10):1290-7. PubMed ID: 25267515
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients.
Worroll D; Galletti G; Gjyrezi A; Nanus DM; Tagawa ST; Giannakakou P
Phys Biol; 2019 Mar; 16(3):036003. PubMed ID: 30763921
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.
Leversha MA; Han J; Asgari Z; Danila DC; Lin O; Gonzalez-Espinoza R; Anand A; Lilja H; Heller G; Fleisher M; Scher HI
Clin Cancer Res; 2009 Mar; 15(6):2091-7. PubMed ID: 19276271
[TBL] [Abstract][Full Text] [Related]
16. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells.
Dago AE; Stepansky A; Carlsson A; Luttgen M; Kendall J; Baslan T; Kolatkar A; Wigler M; Bethel K; Gross ME; Hicks J; Kuhn P
PLoS One; 2014; 9(8):e101777. PubMed ID: 25084170
[TBL] [Abstract][Full Text] [Related]
17. An Accessible and Unique Insight into Metastasis Mutational Content Through Whole-exome Sequencing of Circulating Tumor Cells in Metastatic Prostate Cancer.
Faugeroux V; Lefebvre C; Pailler E; Pierron V; Marcaillou C; Tourlet S; Billiot F; Dogan S; Oulhen M; Vielh P; Rameau P; NgoCamus M; Massard C; Laplace-Builhé C; Tibbe A; Taylor M; Soria JC; Fizazi K; Loriot Y; Julien S; Farace F
Eur Urol Oncol; 2020 Aug; 3(4):498-508. PubMed ID: 31412010
[TBL] [Abstract][Full Text] [Related]
18. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.
Friedlander TW; Roy R; Tomlins SA; Ngo VT; Kobayashi Y; Azameera A; Rubin MA; Pienta KJ; Chinnaiyan A; Ittmann MM; Ryan CJ; Paris PL
Cancer Res; 2012 Feb; 72(3):616-25. PubMed ID: 22158653
[TBL] [Abstract][Full Text] [Related]
19. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.
Cho H; Chung JI; Kim J; Seo WI; Lee CH; Morgan TM; Byun SS; Chung JS; Han KH
Cancer Sci; 2021 Feb; 112(2):859-870. PubMed ID: 33232539
[TBL] [Abstract][Full Text] [Related]
20. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.
Jiang Y; Palma JF; Agus DB; Wang Y; Gross ME
Clin Chem; 2010 Sep; 56(9):1492-5. PubMed ID: 20581083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
